Ali Behbahani - Insider Trading & Ownership

Entity
Individual
Location
2855 Sand Hill Road, Menlo Park, CA
Summary
The estimated net worth of Ali Behbahani is at least $185M dollars as of December 16, 2024. Ali Behbahani is the 10%+ Owner of Savara Inc and owns shares of Savara Inc (SVRA) stock worth about $109M. Ali Behbahani is the Director, 10%+ Owner of Korro Bio, Inc. and owns shares of Korro Bio, Inc. (KRRO) stock worth about $61.1M. Ali Behbahani is the Director of Black Diamond Therapeutics, Inc. and owns shares of Black Diamond Therapeutics, Inc. (BDTX) stock worth about $11.3M. Ali Behbahani is the 10%+ Owner of Trevi Therapeutics, Inc. and owns shares of Trevi Therapeutics, Inc. (TRVI) stock worth about $1.92M. Ali Behbahani is the 10%+ Owner of Metacrine, Inc. and owns shares of Metacrine, Inc. stock worth about $1.2M. Ali Behbahani is the Director of CVRx, Inc. and owns shares of CVRx, Inc. (CVRX) stock worth about $146K. Ali Behbahani is the Director of MINERVA SURGICAL INC and owns shares of MINERVA SURGICAL INC stock worth about $11.9K. Ali Behbahani is the 10%+ Owner of Mirum Pharmaceuticals, Inc. and owns shares of Mirum Pharmaceuticals, Inc. (MIRM) stock worth about $3.79K.
All Insider Reports
All Insider Reports

Ownership of Ali Behbahani

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
SVRA Savara Inc 10%+ Owner $109M Jul 17, 2023
KRRO Korro Bio, Inc. Director, 10%+ Owner $61.1M Jun 11, 2024
BDTX Black Diamond Therapeutics, Inc. Director $11.3M Dec 13, 2024
TRVI Trevi Therapeutics, Inc. 10%+ Owner $1.92M Apr 11, 2022
MTCR Metacrine, Inc. 10%+ Owner $1.2M Dec 10, 2021
CVRX CVRx, Inc. Director $146K Jun 4, 2024
UTRS MINERVA SURGICAL INC Director $11.9K Jun 10, 2022
MIRM Mirum Pharmaceuticals, Inc. 10%+ Owner $3.79K Jun 13, 2023
ADAP Adaptimmune Therapeutics PLC Director Jul 1, 2024
AKUS Akouos, Inc. 10%+ Owner Nov 30, 2022
ACLX Arcellx, Inc. Director May 28, 2024
CRSP CRISPR Therapeutics AG Director May 30, 2024
GNCA GENOCEA BIOSCIENCES, INC. Director, 10%+ Owner May 24, 2022
MBX MBX Biosciences, Inc. 10%+ Owner Sep 16, 2024
GLUE Monte Rosa Therapeutics, Inc. Director, 10%+ Owner Jun 12, 2024
NEUE NeueHealth, Inc. 10%+ Owner Oct 1, 2024
NKTX Nkarta, Inc. Director Jun 13, 2024
OYST Oyster Point Pharma, Inc. Director Jan 3, 2023

Insider Transactions Reported by Ali Behbahani:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.